Phase I Feasibility Study of ALLOSTIM(TM) in Combination With Radiofrequency Ablation in Patients With Refractory Hepatocellular Carcinoma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 10 Dec 2015
Price : $35 *
At a glance
- Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Immunovative Therapies
- 01 Apr 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Jan 2014 Planned initiation date changed from 1 Nov 2013 to 1 Jan 2014, as reported in a Tauriga Sciences media release.
- 20 Aug 2013 New trial record